Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
STEVENSON, Md., Dec. 07, 2015 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Vital Therapies, Inc. (Nasdaq:VTL) (“Vital” or the “Company”) common stock during the period between April 17, 2014 and August 21, 2015, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until February 1, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Vital Therapies common stock purchased on or after April 17, 2014 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company common stock during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including the studies’ independent significance; the degree to which the studies were interrelated; and that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial.
According to the complaint, following the Company’s August 21, 2015 announcement that the VTI-208 trial had failed to meet the primary endpoint of overall survival, the Company would stop the VTI-210 and VTI-212 clinical trials, the value of Vital Therapies shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]
